Minor Use Minor Species Development of Drugs (R01)
ID: 351252Type: Forecasted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$250K - $250K

Eligible Applicants

Unrestricted

Funding Category

Consumer Protection

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351252
Timeline
    Description

    The Food and Drug Administration (FDA) is forecasting a funding opportunity for the development of new animal drugs through its Minor Use Minor Species Development of Drugs (R01) grant program. This initiative aims to support research projects that focus on the development of drugs for minor uses in major species or for minor species, specifically targeting entities that have received a minor use or minor species designation from the FDA's Office of Minor Use and Minor Species Animal Drug Development. The program is crucial for enhancing veterinary medicine by facilitating the approval of drugs that may otherwise be overlooked due to limited market potential. Interested applicants can apply for grants with an award ceiling of $250,000, with an expected six awards available for the fiscal year 2025. For further inquiries, applicants may contact Terrin Brown at terrin.brown@fda.hhs.gov or by phone at (240) 402-7610.

    Point(s) of Contact
    Terrin Brown Grantor
    (240) 402-7610
    terrin.brown@fda.hhs.gov
    Files
    No associated files provided.
    Similar Opportunities
    Minor Use Minor Species Development of Drugs (R01)
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity for research grants (R01) aimed at the development of new animal drugs for minor uses in major species or for minor species (MUMS). Eligible applicants include a variety of organizations such as higher education institutions, nonprofits, and for-profit entities engaged in veterinary drug development, with the goal of defraying costs associated with safety and effectiveness testing required for FDA approval of MUMS-designated drugs. This initiative underscores the FDA's commitment to enhancing veterinary medicine for less common uses and species, with funding available up to $250,000 per year for a maximum of three years. Interested parties must have an open Investigational New Animal Drug (INAD) file and a minor use or minor species designation, with application deadlines spanning from July 2024 to January 2027. For further details, applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov.
    Animal and Veterinary Innovation Centers (U18)
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is inviting applications for the Animal and Veterinary Innovation Centers (U18) funding opportunity, aimed at establishing long-term partnerships to address critical research areas in veterinary medicine. This initiative focuses on driving research to prevent and control Highly Pathogenic Avian Influenza (HPAI), advancing regulatory science for intentional genomic alterations in animals, and developing veterinary products for underrepresented species and conditions. With an estimated total program funding of $3 million and awards of up to $1.25 million available, applications are due by August 5, 2024. Interested applicants, particularly higher education institutions serving minority populations, can find more information and submission guidelines at the provided link or contact Terrin Brown at terrin.brown@fda.hhs.gov.
    Vet-LIRN Capacity-Building Project and Equipment Grants (U18)
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering the Vet-LIRN Capacity-Building Project and Equipment Grants (U18) to enhance the capabilities of veterinary diagnostic laboratories within the Vet-LIRN network. This funding opportunity aims to support projects focused on animal food safety, antimicrobial resistance, and surveillance efforts related to foodborne illnesses and emerging diseases, including COVID-19. The initiative is part of the FDA's commitment to improving food safety standards and aligns with the Food Safety Modernization Act, emphasizing the importance of federal involvement in bolstering food safety and containment capabilities. Interested applicants, including small businesses and various institutions, can apply for grants ranging from $225,000 to $2.5 million, with applications accepted annually until September 4, 2028. For further details, contact Kimberly Pendleton at kimberly.pendleton@fda.hhs.gov or visit the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-202.html.
    Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives." This cooperative agreement aims to enhance the capabilities of State animal food regulatory programs to fully implement the Animal Feed Regulatory Program Standards (AFRPS) and to develop standardized processes that promote mutual reliance between federal and state regulatory efforts. The initiative is crucial for establishing a nationally integrated animal food safety system, ensuring that state programs can effectively manage animal food safety regulations. Interested organizations must meet specific eligibility criteria, including the ability to enter into a 20.88 information disclosure agreement with the FDA, and the funding amount is set at $10.6 million, with approximately 30 awards expected. For further inquiries, applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610.
    Cooperative Agreement for Long Term Data Collection on Antimicrobial Use in Animals (U01) Clinical Trial Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity for the collection of long-term data on antimicrobial use in animals, with a focus on diverse sectors such as livestock, poultry, and companion animals. The primary objectives of this initiative are to gather comprehensive antimicrobial use data and to contribute to the development of data collection frameworks that support antimicrobial stewardship in veterinary settings. This funding is crucial for advancing the FDA's initiatives and the National Action Plan's goals to enhance understanding and management of antimicrobial use in animal agriculture. Interested small businesses can apply for a total estimated funding of $600,000, with an award ceiling of $200,000 per project, and are encouraged to contact Janelle Fundersburg at janelle.fundersburg@fda.hhs.gov or 301-798-2533 for further information.
    Drug Development Tools Research Grants (U01) Clinical Trials Optional
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering Drug Development Tools Research Grants (U01) to support research aimed at advancing drug development tools (DDTs) that have an accepted or reviewable Letter of Intent within the FDA's qualification program. These grants are intended for developers working towards their qualification plan or full qualification package, focusing on tools that can enhance public health by optimizing the drug development process, such as biomarkers or animal models. The funding opportunity provides up to $500,000 for a maximum two-year period, with applications due by May 13, 2024, and May 13, 2025. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov for further information and are encouraged to review the detailed announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-030.html.
    Collaborations to Enhance Drug Development and Regulatory Science
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is inviting applications for a federal grant titled "Collaborations to Enhance Drug Development and Regulatory Science." This opportunity aims to establish cooperative agreements that support Public-Private Partnerships and collaborative activities under the Critical Path Initiative, focusing on innovative projects that enhance drug product development, advanced manufacturing, and the translation of scientific discoveries into therapeutics. The initiative is crucial for fostering innovation in drug safety, efficacy, quality, and performance, with a total funding ceiling of $5 million available for six expected awards in fiscal year 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call (240) 402-7610 for further information.
    Animal Food Regulatory Program Alliance
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Animal Food Regulatory Program Alliance," aimed at enhancing the national food safety system through improved collaboration among federal and state agencies. The primary objective of this program is to support the development of a national integrated animal food safety system, which includes sharing best practices, conducting training programs, and advancing the Animal Food Regulatory Program Standards (AFRPS). This initiative is crucial for ensuring public health and consumer protection in the regulation of manufactured foods. Interested national associations or organizations that represent state animal food regulatory programs can apply for funding, with a total award amount of $600,000. For further inquiries, applicants may contact Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610. The fiscal year for this opportunity is 2025.
    Development and Maintenance of Human and Animal Food Rapid Response Teams (U2F) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "Development and Maintenance of Human and Animal Food Rapid Response Teams (U2F) Clinical Trials Not Allowed." This initiative aims to establish and sustain Rapid Response Teams (RRTs) to enhance the national integrated food safety system by coordinating federal, state, and local emergency response efforts related to human and animal food safety. The program is critical for improving regulatory and surveillance capabilities, ensuring rapid identification and removal of contaminated food, and fostering continuous improvement in response strategies. Interested applicants, including state governments and other entities, can apply for funding ranging from $360,000 to $1,440,000, with an expected four awards to be made. For further inquiries, applicants may contact Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610.
    Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) has announced a funding opportunity for clinical studies of orphan products addressing unmet needs in rare diseases through the Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) program. This initiative aims to support clinical trials that evaluate the safety and efficacy of products intended for rare diseases, with the goal of increasing the number of approved treatments and improving drug development for conditions affecting approximately 30 million Americans. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and for-profit entities, with grants available up to $650,000 per year for a maximum of four years. Interested parties should submit their applications by September 22, 2024, and can reach out to Shashi Malhotra at shashi.malhotra@fda.hhs.gov for further information.